{"entity":{"edinet_code":"E03003","sec_code":"3055","name_ja":"株式会社ほくやく・竹山ホールディングス","name_en":"HOKUYAKU TAKEYAMA Holdings,Inc.","industry":"卸売業","industry_en":"Wholesale Trade"},"names_note":"English company names are as filed: each company's own annual report states its English name on the cover page. For a company that files no annual report, EDINET's filer registry is used instead. The as-filed Japanese name is always returned alongside.","filing":{"doc_id":"S100YJPG","filer_name":"株式会社ほくやく・竹山ホールディングス","filer_name_en":"HOKUYAKU TAKEYAMA Holdings,Inc.","period_end":"2026-03-31","filed_date":"2026-06-25","sha256":"5c0e9f2180734e1177e3b9d5b242b5ca80e4e02256a9834841b4ed6f59db1213","status":"clean"},"basis":{"measurement":"carrying_amount","entity_scope":"holdco_consolidated","share_scope":"both","trust_included":"unknown","as_of":"2026-03-31","period_type":"annual","labels":{"measurement":"Balance-sheet carrying amount. Under Japanese GAAP listed equities are carried at market with the valuation difference in other comprehensive income, so carrying amount and acquisition cost diverge enormously on positions bought decades ago.","entity_scope":"Every disclosing entity in the filing, summed — the reporting company plus each group holder it names.","share_scope":"Listed and unlisted shares together.","trust_included":"The filing does not state whether retirement-benefit-trust shares are included. Never guessed — shares contributed to such a trust leave the holder's balance sheet while the settlor normally keeps the right to instruct the vote.","period_type":"From an annual securities report (有価証券報告書). The policy shareholding table appears only in the annual report."},"not_comparable":"Figures are balance-sheet CARRYING AMOUNT at fiscal year end, from the annual securities report. They are NOT comparable with the acquisition-cost or book-value-reduction figures quoted in press coverage and IR presentations, and NOT comparable with interim (half-year) figures, which this product does not hold. Always state the basis with the number, and use check_claim before setting one of our figures against a published one."},"basis_note":"The basis every yen figure on this response is on. entity_scope is read from the filing's own disclosing entities, not assumed: scale_entities and flows each carry their own entity_scope and share_scope, and a figure quoted for one entity is not the group figure.","holdings":[{"holder_table":"reporting","held_name_raw":"塩野義製薬株式会社","held_name_en":"Shionogi & Co., Ltd.","held_sec_code":"4507","match_status":"matched","shares":837000,"book_value_yen":2903000000,"prior_shares":837000,"prior_book_value_yen":1879000000,"purpose_ja":"（保有目的）主として医薬品卸売事業における安定的な商品取引関係および医薬品専門情報収集等の強化のため（定量的な保有効果）　（注）","reciprocal":"有","pct_outstanding":0.0973283546875949,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":4.489429813030636,"pct_of_holder_assets":1.864662620034043,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"大塚ホールディングス株式会社","held_name_en":"Otsuka Holdings Co., Ltd.","held_sec_code":"4578","match_status":"matched","shares":170600,"book_value_yen":1878000000,"prior_shares":170600,"prior_book_value_yen":1322000000,"purpose_ja":"（保有目的）主として医薬品卸売事業における安定的な商品取引関係および医薬品専門情報収集等の強化のため（定量的な保有効果）　（注）","reciprocal":"有","pct_outstanding":0.03230256608650116,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":2.9042883874858885,"pct_of_holder_assets":1.2062819154061084,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"東邦ホールディングス株式会社","held_name_en":"TOHO HOLDINGS CO.,LTD.","held_sec_code":"8129","match_status":"matched","shares":260800,"book_value_yen":1241000000,"prior_shares":260800,"prior_book_value_yen":1163000000,"purpose_ja":"（保有目的）業界動向把握のため（定量的な保有効果）　（注）","reciprocal":"有","pct_outstanding":0.40322055722298045,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":1.9191809844888112,"pct_of_holder_assets":0.797122394578797,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"アステラス製薬株式会社","held_name_en":"Astellas Pharma Inc.","held_sec_code":"4503","match_status":"matched","shares":468000,"book_value_yen":1178000000,"prior_shares":468000,"prior_book_value_yen":676000000,"purpose_ja":"（保有目的）主として医薬品卸売事業における安定的な商品取引関係および医薬品専門情報収集等の強化のため （定量的な保有効果）　（注）","reciprocal":"無","pct_outstanding":0.025867911617028994,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":1.8217527797967925,"pct_of_holder_assets":0.7566560683431287,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"エーザイ株式会社","held_name_en":"Eisai Co., Ltd.","held_sec_code":"4523","match_status":"matched","shares":217400,"book_value_yen":1058000000,"prior_shares":217400,"prior_book_value_yen":901000000,"purpose_ja":"（保有目的）主として医薬品卸売事業における安定的な商品取引関係および医薬品専門情報収集等の強化のため（定量的な保有効果）　（注）","reciprocal":"有","pct_outstanding":0.07706106017466013,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":1.6361752470500905,"pct_of_holder_assets":0.6795773517037608,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"キッセイ薬品工業株式会社","held_name_en":"KISSEI PHARMACEUTICAL CO., LTD.","held_sec_code":"4547","match_status":"matched","shares":154797,"book_value_yen":719000000,"prior_shares":153755,"prior_book_value_yen":591000000,"purpose_ja":"（保有目的）主として医薬品卸売事業における安定的な商品取引関係および医薬品専門情報収集等の強化のため（株式数が増加した理由）医薬品専門情報収集等を強化するため取引先持株会に加入し株式を取得（定量的な保有効果）　（注）","reciprocal":"有","pct_outstanding":0.3734359803614221,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":1.111918717040657,"pct_of_holder_assets":0.4618299771975463,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"小野薬品工業株式会社","held_name_en":"ONO　PHARMACEUTICAL　CO.,　LTD.","held_sec_code":"4528","match_status":"matched","shares":263850,"book_value_yen":662000000,"prior_shares":263850,"prior_book_value_yen":422000000,"purpose_ja":"（保有目的）主として医薬品卸売事業における安定的な商品取引関係および医薬品専門情報収集等の強化のため （定量的な保有効果）　（注）","reciprocal":"有","pct_outstanding":0.05516346554097097,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":1.0237693889859734,"pct_of_holder_assets":0.4252175867938465,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"株式会社ほくほくフィナンシャルグループ","held_name_en":"Hokuhoku Financial Group, Inc.","held_sec_code":"8377","match_status":"matched","shares":105000,"book_value_yen":612000000,"prior_shares":105000,"prior_book_value_yen":269000000,"purpose_ja":"（保有目的）当社グループの安定的な資金調達および金融専門情報取得等の金融取引関係の円滑化のため（定量的な保有効果）　（注）","reciprocal":"有","pct_outstanding":0.08726263545093266,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.9464454170081809,"pct_of_holder_assets":0.3931014548607766,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"第一三共株式会社","held_name_en":"DAIICHI SANKYO COMPANY, LIMITED","held_sec_code":"4568","match_status":"matched","shares":216342,"book_value_yen":598000000,"prior_shares":216342,"prior_book_value_yen":759000000,"purpose_ja":"（保有目的）主として医薬品卸売事業における安定的な商品取引関係および医薬品専門情報収集等の強化のため （定量的な保有効果）　（注）","reciprocal":"有","pct_outstanding":0.0117972945640017,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.924794704854399,"pct_of_holder_assets":0.38410893791951695,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"株式会社バイタルケーエスケーホールディングス","held_name_en":null,"held_sec_code":null,"match_status":"unmatched","shares":307300,"book_value_yen":450000000,"prior_shares":307300,"prior_book_value_yen":386000000,"purpose_ja":"（保有目的）主として医薬品卸売事業における協業関係維持・強化のため（定量的な保有効果）　（注）","reciprocal":"有","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":null,"pct_share_classes":null,"pct_of_holder_equity":0.695915747800133,"pct_of_holder_assets":0.28904518739762985,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"株式会社北洋銀行","held_name_en":"North Pacific Bank,Ltd.","held_sec_code":"8524","match_status":"matched","shares":440500,"book_value_yen":411000000,"prior_shares":440500,"prior_book_value_yen":227000000,"purpose_ja":"（保有目的）当社グループの安定的な資金調達および金融専門情報取得等の金融取引関係の円滑化のため（定量的な保有効果）　（注）","reciprocal":"有","pct_outstanding":0.11736483186232925,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.6356030496574548,"pct_of_holder_assets":0.26399460448983525,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"住友ファーマ株式会社","held_name_en":"Sumitomo Pharma Co., Ltd.","held_sec_code":"4506","match_status":"matched","shares":168000,"book_value_yen":348000000,"prior_shares":168000,"prior_book_value_yen":122000000,"purpose_ja":"（保有目的）主として医薬品卸売事業における安定的な商品取引関係および医薬品専門情報収集等の強化のため （定量的な保有効果）　（注）","reciprocal":"有","pct_outstanding":0.042286591666328664,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.5381748449654362,"pct_of_holder_assets":0.22352827825416707,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"持田製薬株式会社","held_name_en":"Mochida Pharmaceutical Co.,Ltd.","held_sec_code":"4534","match_status":"matched","shares":80800,"book_value_yen":279000000,"prior_shares":80800,"prior_book_value_yen":256000000,"purpose_ja":"（保有目的）主として医薬品卸売事業における安定的な商品取引関係および医薬品専門情報収集等の強化のため （定量的な保有効果）　（注）","reciprocal":"有","pct_outstanding":0.22792858613754136,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.43146776363608247,"pct_of_holder_assets":0.17920801618653048,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"ゼリア新薬工業株式会社","held_name_en":"ZERIA PHARMACEUTICAL CO., LTD.","held_sec_code":"4559","match_status":"matched","shares":115500,"book_value_yen":253000000,"prior_shares":115500,"prior_book_value_yen":260000000,"purpose_ja":"（保有目的）主として医薬品卸売事業における安定的な商品取引関係および医薬品専門情報収集等の強化のため （定量的な保有効果）　（注）","reciprocal":"有","pct_outstanding":0.26202662508118857,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.39125929820763033,"pct_of_holder_assets":0.1625076275813341,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"杏林製薬株式会社","held_name_en":"KYORIN Pharmaceutical Co., Ltd.","held_sec_code":"4569","match_status":"matched","shares":50000,"book_value_yen":82000000,"prior_shares":50000,"prior_book_value_yen":75000000,"purpose_ja":"（保有目的）主として医薬品卸売事業における安定的な商品取引関係および医薬品専門情報収集等の強化のため （定量的な保有効果）　（注）","reciprocal":"有","pct_outstanding":0.08605031317064925,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.1268113140435798,"pct_of_holder_assets":0.05267045637023477,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"中道リース株式会社","held_name_en":"Nakamichi Leasing Co., Ltd.","held_sec_code":"8594","match_status":"matched","shares":100000,"book_value_yen":66000000,"prior_shares":100000,"prior_book_value_yen":55000000,"purpose_ja":"（保有目的）地場企業としての関係強化のため（定量的な保有効果）　（注）","reciprocal":"有","pct_outstanding":1.3863856924996534,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":0.10206764301068617,"pct_of_holder_assets":0.042393294151652376,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"明治ホールディングス株式会社","held_name_en":"Meiji Holdings Co.,Ltd.","held_sec_code":"2269","match_status":"matched","shares":16800,"book_value_yen":64000000,"prior_shares":16800,"prior_book_value_yen":54000000,"purpose_ja":"（保有目的）主として医薬品卸売事業における安定的な商品取引関係および医薬品専門情報収集等の強化のため （定量的な保有効果）　（注）","reciprocal":"無","pct_outstanding":0.00619692956894453,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.09897468413157447,"pct_of_holder_assets":0.04110864887432958,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"協和キリン株式会社","held_name_en":"Kyowa Kirin Co., Ltd.","held_sec_code":"4151","match_status":"matched","shares":20200,"book_value_yen":52000000,"prior_shares":20200,"prior_book_value_yen":43000000,"purpose_ja":"（保有目的）主として医薬品卸売事業における安定的な商品取引関係および医薬品専門情報収集等の強化のため （定量的な保有効果）　（注）","reciprocal":"有","pct_outstanding":0.003858730722106057,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":0.08041693085690425,"pct_of_holder_assets":0.03340077721039278,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"小林製薬株式会社","held_name_en":"KOBAYASHI PHARMACEUTICAL CO.,LTD.","held_sec_code":"4967","match_status":"matched","shares":6832,"book_value_yen":40000000,"prior_shares":6615,"prior_book_value_yen":37000000,"purpose_ja":"（保有目的）主として医薬品卸売事業における安定的な商品取引関係および医薬品専門情報収集等の強化のため（株式数が増加した理由）医薬品専門情報収集等を強化するため取引先持株会に加入し株式を取得（定量的な保有効果）　（注）","reciprocal":"無","pct_outstanding":0.009190355507487341,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":0.06185917758223405,"pct_of_holder_assets":0.025692905546455983,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"株式会社三井住友フィナンシャルグループ","held_name_en":"Sumitomo Mitsui Financial Group, Inc.","held_sec_code":"8316","match_status":"matched","shares":6300,"book_value_yen":31000000,"prior_shares":6300,"prior_book_value_yen":23000000,"purpose_ja":"（保有目的）当社グループの安定的な資金調達および金融専門情報取得等の金融取引関係の円滑化のため（定量的な保有効果）　（注）","reciprocal":"無","pct_outstanding":0.00016503207028928583,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.04794086262623139,"pct_of_holder_assets":0.019912001798503387,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"わかもと製薬株式会社","held_name_en":"WAKAMOTO PHARMACEUTICAL CO.,LTD.","held_sec_code":"4512","match_status":"matched","shares":77400,"book_value_yen":27000000,"prior_shares":77400,"prior_book_value_yen":24000000,"purpose_ja":"（保有目的）主として医薬品卸売事業における安定的な商品取引関係および医薬品専門情報収集等の強化のため（定量的な保有効果）　（注）","reciprocal":"有","pct_outstanding":0.22301667510662804,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.04175494486800798,"pct_of_holder_assets":0.01734271124385779,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"扶桑薬品工業株式会社","held_name_en":"Fuso Pharmaceutical Industries, Ltd.","held_sec_code":"4538","match_status":"matched","shares":10300,"book_value_yen":24000000,"prior_shares":10300,"prior_book_value_yen":25000000,"purpose_ja":"（保有目的）主として医薬品卸売事業における安定的な商品取引関係および医薬品専門情報収集等の強化のため（定量的な保有効果）　（注）","reciprocal":"有","pct_outstanding":0.12065030750015023,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.03711550654934043,"pct_of_holder_assets":0.01541574332787359,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"第一生命ホールディングス株式会社","held_name_en":"Daiichi Life Group, Inc.","held_sec_code":"8750","match_status":"matched","shares":11600,"book_value_yen":16000000,"prior_shares":11600,"prior_book_value_yen":13000000,"purpose_ja":"（保有目的）保険取引関係の円滑化のため（定量的な保有効果）　（注）","reciprocal":"有","pct_outstanding":0.0003205277860040359,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.024743671032893617,"pct_of_holder_assets":0.010277162218582395,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"武田薬品工業株式会社","held_name_en":"Takeda Pharmaceutical Company Limited","held_sec_code":"4502","match_status":"matched","shares":1000,"book_value_yen":5000000,"prior_shares":1000,"prior_book_value_yen":4000000,"purpose_ja":"（保有目的）主として医薬品卸売事業における安定的な商品取引関係および医薬品専門情報収集等の強化のため （定量的な保有効果）　（注）","reciprocal":"無","pct_outstanding":6.309391449232193e-05,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.007732397197779256,"pct_of_holder_assets":0.003211613193306998,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"日本ケミファ株式会社","held_name_en":"NIPPON CHEMIPHAR CO., LTD.","held_sec_code":"4539","match_status":"matched","shares":2800,"book_value_yen":4000000,"prior_shares":2800,"prior_book_value_yen":4000000,"purpose_ja":"（保有目的）主として医薬品卸売事業における安定的な商品取引関係および医薬品専門情報収集等の強化のため（定量的な保有効果）　（注）","reciprocal":"有","pct_outstanding":0.07668879686233265,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.006185917758223404,"pct_of_holder_assets":0.0025692905546455987,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"日本ハム株式会社","held_name_en":"NH Foods Ltd.","held_sec_code":"2282","match_status":"matched","shares":500,"book_value_yen":3000000,"prior_shares":500,"prior_book_value_yen":2000000,"purpose_ja":"（保有目的）地場関連企業としての支援のため（定量的な保有効果）　（注）","reciprocal":"無","pct_outstanding":0.0005306047289361171,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.004639438318667553,"pct_of_holder_assets":0.0019269679159841988,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"森下仁丹株式会社","held_name_en":"MORISHITA JINTAN CO., LTD.","held_sec_code":"4524","match_status":"matched","shares":1300,"book_value_yen":2000000,"prior_shares":1300,"prior_book_value_yen":2000000,"purpose_ja":"（保有目的）主として医薬品卸売事業における安定的な商品取引関係および医薬品専門情報収集等の強化のため（定量的な保有効果）　（注）","reciprocal":"無","pct_outstanding":0.03171659998048209,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.003092958879111702,"pct_of_holder_assets":0.0012846452773227993,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"北海道電力株式会社","held_name_en":"Hokkaido Electric Power Company, Incorporated","held_sec_code":"9509","match_status":"matched","shares":2800,"book_value_yen":2000000,"prior_shares":2800,"prior_book_value_yen":2000000,"purpose_ja":"（保有目的）地場企業としての関係強化のため（定量的な保有効果）　（注）","reciprocal":"無","pct_outstanding":0.0013609296689433593,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":2,"pct_of_holder_equity":0.003092958879111702,"pct_of_holder_assets":0.0012846452773227993,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"アステナホールディングス株式会社","held_name_en":"Astena Holdings Co., Ltd.","held_sec_code":"8095","match_status":"matched","shares":2800,"book_value_yen":1000000,"prior_shares":2800,"prior_book_value_yen":1000000,"purpose_ja":"（保有目的）主として医薬品卸売事業における安定的な商品取引関係および医薬品専門情報収集等の強化のため（定量的な保有効果）　（注）","reciprocal":"無","pct_outstanding":0.006825661346859974,"pct_unavailable":null,"pct_basis_period_end":"2025-11-30","pct_share_classes":1,"pct_of_holder_equity":0.001546479439555851,"pct_of_holder_assets":0.0006423226386613997,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"雪印メグミルク株式会社","held_name_en":"MEGMILK SNOW BRAND Co.,Ltd.","held_sec_code":"2270","match_status":"matched","shares":100,"book_value_yen":0,"prior_shares":100,"prior_book_value_yen":0,"purpose_ja":"（保有目的）地場関連企業として関係強化（定量的な保有効果）　（注）","reciprocal":"無","pct_outstanding":0.0001645815419661125,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0,"pct_of_holder_assets":0.0,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"鳥居薬品株式会社","held_name_en":"TORII PHARMACEUTICAL CO., LTD.","held_sec_code":null,"match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":37200,"prior_book_value_yen":170000000,"purpose_ja":"（保有目的）主として医薬品卸売事業における安定的な商品取引関係および医薬品専門情報収集等の強化のため （定量的な保有効果）　（注）","reciprocal":"有","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2024-12-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"久光製薬株式会社","held_name_en":"HISAMITSU PHARMACEUTICAL CO.,INC.","held_sec_code":null,"match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":52300,"prior_book_value_yen":211000000,"purpose_ja":"（保有目的）主として医薬品卸売事業における安定的な商品取引関係および医薬品専門情報収集等の強化のため（定量的な保有効果）　（注）","reciprocal":"有","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2025-02-28","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false}],"holders":[{"holder_name":"田辺三菱製薬株式会社","holder_name_en":"Mitsubishi Tanabe Pharma Corporation","holder_sec_code":"4508","doc_id":"S100G3TB","period_end":"2019-03-31","holder_table":"reporting","shares":1176342,"book_value_yen":901000000,"prior_shares":1176342,"prior_book_value_yen":994000000,"purpose_ja":null,"reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":null,"pct_share_classes":null,"pct_of_holder_equity":0.10037834055997968,"pct_of_holder_assets":0.0852988679202413,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":897604000000,"holder_total_assets_yen":1056286000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社ほくほくフィナンシャルグループ","holder_name_en":"Hokuhoku Financial Group, Inc.","holder_sec_code":"8377","doc_id":"S100YBV5","period_end":"2026-03-31","holder_table":"second_largest","shares":896000,"book_value_yen":825000000,"prior_shares":896000,"prior_book_value_yen":794000000,"purpose_ja":"株式保有を通して企業の成長を支援し、長期的な取引関係を維持するために保有しております。株式数は増加しておりません。","reciprocal":"無（注３）","pct_outstanding":4.358782265204659,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.11262414252073308,"pct_of_holder_assets":0.004863301438918261,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":732525000000,"holder_total_assets_yen":16963785000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社北洋銀行","holder_name_en":"North Pacific Bank,Ltd.","holder_sec_code":"8524","doc_id":"S100YBAP","period_end":"2026-03-31","holder_table":"reporting","shares":808858,"book_value_yen":744000000,"prior_shares":808858,"prior_book_value_yen":717000000,"purpose_ja":"北海道内に本社及び事業基盤（営業拠点等）を有し、雇用創出、地域経済の活性化に寄与。中長期的に保有することによって、当行の企業価値向上に資するため保有。","reciprocal":"無（注２）","pct_outstanding":3.934861501639408,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.18997717209786888,"pct_of_holder_assets":0.005606079340942079,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":391626000000,"holder_total_assets_yen":13271307000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"エーザイ株式会社","holder_name_en":"Eisai Co., Ltd.","holder_sec_code":"4523","doc_id":"S100YB05","period_end":"2026-03-31","holder_table":"reporting","shares":546005,"book_value_yen":503000000,"prior_shares":546005,"prior_book_value_yen":484000000,"purpose_ja":"・医療用医薬品販売事業等における取引関係の強化のため保有しています。・定量的な保有効果を検証しています。","reciprocal":"有","pct_outstanding":2.6561572664208364,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.05595155463007457,"pct_of_holder_assets":0.03471088866085668,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":898992000000,"holder_total_assets_yen":1449113000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"住友ファーマ株式会社","holder_name_en":"Sumitomo Pharma Co., Ltd.","holder_sec_code":"4506","doc_id":"S100YH3M","period_end":"2026-03-31","holder_table":"reporting","shares":468300,"book_value_yen":431000000,"prior_shares":468300,"prior_book_value_yen":415000000,"purpose_ja":"重要な特約店として同社と良好な関係を維持・強化していくことの事業上の必要性等に加え、資本コストを勘案した配当・取引額等の定量的な評価の実施を通じて、総合的に判断し保有しています。","reciprocal":"有","pct_outstanding":2.278144793298372,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.14736705337696218,"pct_of_holder_assets":0.05356892058003582,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":292467000000,"holder_total_assets_yen":804571000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社バイタルケーエスケー・ホールディングス","holder_name_en":"VITAL KSK HOLDINGS,INC.","holder_sec_code":"3151","doc_id":"S100YDSN","period_end":"2026-03-31","holder_table":"second_largest","shares":457781,"book_value_yen":421000000,"prior_shares":457781,"prior_book_value_yen":406000000,"purpose_ja":"①取引関係の維持・強化及び同業者としての情報収集のため　②業務提携契約締結のため　③ＡがＢを下回っております　④該当なし","reciprocal":"無(注４)","pct_outstanding":2.2269728840933634,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.3546547381367569,"pct_of_holder_assets":0.13132939033216043,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"第一三共株式会社","holder_name_en":"DAIICHI SANKYO COMPANY, LIMITED","holder_sec_code":"4568","doc_id":"S100YZB3","period_end":"2026-03-31","holder_table":"reporting","shares":438500,"book_value_yen":403000000,"prior_shares":438500,"prior_book_value_yen":388000000,"purpose_ja":"同社グループ会社と行っている医薬品販売等に関する取引における取引関係の構築・維持・強化を目的として保有しております。","reciprocal":"有","pct_outstanding":2.1331763652815208,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0239306474398067,"pct_of_holder_assets":0.010084365854787634,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1684033000000,"holder_total_assets_yen":3996285000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"大塚ホールディングス株式会社","holder_name_en":"Otsuka Holdings Co., Ltd.","holder_sec_code":"4578","doc_id":"S100XUA7","period_end":"2025-12-31","holder_table":"largest","shares":423204,"book_value_yen":385000000,"prior_shares":419878,"prior_book_value_yen":370000000,"purpose_ja":"医薬品販売等に係る事業上の関係の維持・強化を目的として保有しています。これにより、大塚製薬㈱の事業基盤の安定化に資する協力関係の構築を図っています。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。持株会により株式が増加しております。","reciprocal":"有","pct_outstanding":2.05876572518267,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.012691844649184228,"pct_of_holder_assets":0.009171990788938912,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"塩野義製薬株式会社","holder_name_en":"Shionogi & Co., Ltd.","holder_sec_code":"4507","doc_id":"S100Z43Z","period_end":"2026-03-31","holder_table":"reporting","shares":367530,"book_value_yen":338000000,"prior_shares":367530,"prior_book_value_yen":325000000,"purpose_ja":"同社グループは当社の取引先の一つであるため、医薬品販売等における取引関係維持・強化のために株式を保有しております。2026年５月の取締役会において、個別の政策保有株式について、保有目的、保有に伴う便益・リスク、資本コスト等を総合的に検証し、経済合理性・戦略妥当性を確認しております。","reciprocal":"有","pct_outstanding":1.787927729833335,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.02005678800627813,"pct_of_holder_assets":0.013116688075067814,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1685215000000,"holder_total_assets_yen":2576870000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"キッセイ薬品工業株式会社","holder_name_en":"KISSEI PHARMACEUTICAL CO., LTD.","holder_sec_code":"4547","doc_id":"S100YFN3","period_end":"2026-03-31","holder_table":"reporting","shares":292000,"book_value_yen":268000000,"prior_shares":292000,"prior_book_value_yen":259000000,"purpose_ja":"同社は医薬品事業における取引先の一つであるため、取引関係維持・強化のために株式を保有しています。具体的には、医療用医薬品の販売先です。2026年４月の取締役会において、個別の政策保有株式について、保有目的、保有に伴う便益・リスク、資本コスト等を総合的に検証し、経済合理性・戦略妥当性を確認しています。","reciprocal":"有","pct_outstanding":1.420496006071161,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.1157487388570244,"pct_of_holder_assets":0.0974240782882444,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":231536000000,"holder_total_assets_yen":275086000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"ゼリア新薬工業株式会社","holder_name_en":"ZERIA PHARMACEUTICAL CO., LTD.","holder_sec_code":"4559","doc_id":"S100YKC2","period_end":"2026-03-31","holder_table":"reporting","shares":289418,"book_value_yen":266553000,"prior_shares":289418,"prior_book_value_yen":256713000,"purpose_ja":"（保有目的）医療用医薬品事業活動の円滑な推進（定量的な保有効果）（注）１","reciprocal":"有","pct_outstanding":1.4079353187846002,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.2454339260726898,"pct_of_holder_assets":0.14833391337148763,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":108604790000,"holder_total_assets_yen":179697949000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"持田製薬株式会社","holder_name_en":"Mochida Pharmaceutical Co.,Ltd.","holder_sec_code":"4534","doc_id":"S100YI28","period_end":"2026-03-31","holder_table":"reporting","shares":251500,"book_value_yen":231000000,"prior_shares":251500,"prior_book_value_yen":223000000,"purpose_ja":"取引関係の維持・強化のため、保有しております。保有効果を定量的に量りかねるため、取引関係への影響を含む現在及び将来の意義を総合的に判断のうえ、保有の適否を取締役会において、検証しました。なお、同社子会社と医薬品販売等の重要な取引を行っております。","reciprocal":"無(注)","pct_outstanding":1.2234751559140309,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.16461667830622978,"pct_of_holder_assets":0.12642294220665498,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":140326000000,"holder_total_assets_yen":182720000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"小野薬品工業株式会社","holder_name_en":"ONO　PHARMACEUTICAL　CO.,　LTD.","holder_sec_code":"4528","doc_id":"S100YOIE","period_end":"2026-03-31","holder_table":"reporting","shares":249606,"book_value_yen":230000000,"prior_shares":249606,"prior_book_value_yen":221000000,"purpose_ja":"取引先(特約店)として、事業上の関係を維持・強化することで、企業基盤の安定化を図り、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有","pct_outstanding":1.2142613907239665,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.027035700054188948,"pct_of_holder_assets":0.02078598121128046,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"アルフレッサホールディングス株式会社","holder_name_en":"Alfresa Holdings Corporation","holder_sec_code":"2784","doc_id":"S100YH29","period_end":"2026-03-31","holder_table":"largest","shares":168536,"book_value_yen":155000000,"prior_shares":168536,"prior_book_value_yen":149000000,"purpose_ja":"・同業界内における関係維持発展に伴う中　長期的な企業価値の向上・当社グループの取引先・検証実施(注)１","reciprocal":"無(注)３","pct_outstanding":0.8198791605452369,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.030517638210445695,"pct_of_holder_assets":0.010285225903374615,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":507903000000,"holder_total_assets_yen":1507016000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"久光製薬株式会社","holder_name_en":"HISAMITSU PHARMACEUTICAL CO.,INC.","holder_sec_code":"4530","doc_id":"S100VT69","period_end":"2025-02-28","holder_table":"reporting","shares":172500,"book_value_yen":151000000,"prior_shares":172500,"prior_book_value_yen":138000000,"purpose_ja":"医薬品事業の販売先であり、取引関係維持・強化を図るため。","reciprocal":"有","pct_outstanding":0.8207602380918395,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.054043026838983994,"pct_of_holder_assets":0.04401459768908788,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"テルモ株式会社","holder_name_en":"TERUMO CORPORATION","holder_sec_code":"4543","doc_id":"S100YGMG","period_end":"2026-03-31","holder_table":"reporting","shares":140368,"book_value_yen":129000000,"prior_shares":140368,"prior_book_value_yen":124000000,"purpose_ja":"主にメディカルケアソリューションズカンパニーにおける代理店取引関係維持・強化のため保有しております。 ","reciprocal":"無 (注)１","pct_outstanding":0.6828499430828655,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.008141323274276132,"pct_of_holder_assets":0.005579020116476101,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1584509000000,"holder_total_assets_yen":2312234000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"杏林製薬株式会社","holder_name_en":"KYORIN Pharmaceutical Co., Ltd.","holder_sec_code":"4569","doc_id":"S100YDHG","period_end":"2026-03-31","holder_table":"reporting","shares":123800,"book_value_yen":114000000,"prior_shares":123800,"prior_book_value_yen":109000000,"purpose_ja":"医薬品の安定供給を図るため、同社の充実した販売網を経常的に活用するために保有するものであり、当社の持続成長や企業価値向上の観点から総合的に保有の適否を検証しております","reciprocal":"有","pct_outstanding":0.6022513888753758,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.08004212743549237,"pct_of_holder_assets":0.058325445754777314,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":142425000000,"holder_total_assets_yen":195455000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"あすか製薬ホールディングス株式会社","holder_name_en":"ASKA Pharmaceutical Holdings Co., Ltd.","holder_sec_code":"4886","doc_id":"S100YEAY","period_end":"2026-03-31","holder_table":"largest","shares":112500,"book_value_yen":103000000,"prior_shares":112500,"prior_book_value_yen":99000000,"purpose_ja":"医薬品事業等における特約店であり、中長期的な取引関係の維持と強化を図るため","reciprocal":"有","pct_outstanding":0.5472801393253617,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.13408141215063982,"pct_of_holder_assets":0.09165413466928875,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":76819000000,"holder_total_assets_yen":112379000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"東邦ホールディングス株式会社","holder_name_en":"TOHO HOLDINGS CO.,LTD.","holder_sec_code":"8129","doc_id":"S100YHSN","period_end":"2026-03-31","holder_table":"reporting","shares":100766,"book_value_yen":92000000,"prior_shares":100766,"prior_book_value_yen":89000000,"purpose_ja":"同上","reciprocal":"有","pct_outstanding":0.4901976046156391,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.03387833259684784,"pct_of_holder_assets":0.012419325009685723,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"中道リース株式会社","holder_name_en":"Nakamichi Leasing Co., Ltd.","holder_sec_code":"8594","doc_id":"S100XSCO","period_end":"2025-12-31","holder_table":"reporting","shares":80375,"book_value_yen":73222000,"prior_shares":80375,"prior_book_value_yen":70891000,"purpose_ja":"商品仕入先として、安定的かつ良好な関係を維持するため ","reciprocal":"無","pct_outstanding":0.3910012550957862,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.5544794078848726,"pct_of_holder_assets":0.047733319234939627,"holder_equity_basis":"parent_only","holder_equity_yen":13205540000,"holder_total_assets_yen":153398090000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"科研製薬株式会社","holder_name_en":"KAKEN PHARMACEUTICAL CO., LTD.","holder_sec_code":"4521","doc_id":"S100YK2Q","period_end":"2026-03-31","holder_table":"reporting","shares":63365,"book_value_yen":58000000,"prior_shares":63365,"prior_book_value_yen":56000000,"purpose_ja":"医薬品販売に係る取引円滑化のため、当社の持続成長や企業価値向上から総合的に判断し保有しております。","reciprocal":"有","pct_outstanding":0.3082524980297915,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.03929033525494686,"pct_of_holder_assets":0.0325445945111858,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":147619000000,"holder_total_assets_yen":178217000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"扶桑薬品工業株式会社","holder_name_en":"Fuso Pharmaceutical Industries, Ltd.","holder_sec_code":"4538","doc_id":"S100YHSC","period_end":"2026-03-31","holder_table":"reporting","shares":58000,"book_value_yen":53000000,"prior_shares":58000,"prior_book_value_yen":51000000,"purpose_ja":"・製商品の販売を行う取引先企業との業務　のより円滑な推進・株価の評価益及び受取配当金の発生","reciprocal":"無(注)3","pct_outstanding":0.2821533162744087,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.15118236015631686,"pct_of_holder_assets":0.058678298993611815,"holder_equity_basis":"parent_only","holder_equity_yen":35057000000,"holder_total_assets_yen":90323000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"協和キリン株式会社","holder_name_en":"Kyowa Kirin Co., Ltd.","holder_sec_code":"4151","doc_id":"S100XPTY","period_end":"2025-12-31","holder_table":"reporting","shares":52000,"book_value_yen":47000000,"prior_shares":52000,"prior_book_value_yen":46000000,"purpose_ja":"医薬品販売等における円滑な取引関係の維持のため保有しています。なお、定量的な保有効果の記載は困難ですが、取締役会において保有の合理性を検証しています。","reciprocal":"有","pct_outstanding":0.25296504217705607,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.00526120188239087,"pct_of_holder_assets":0.0042424133013196615,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":893332000000,"holder_total_assets_yen":1107860000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"大正製薬ホールディングス株式会社","holder_name_en":"TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.","holder_sec_code":"4581","doc_id":"S100R80T","period_end":"2023-03-31","holder_table":"reporting","shares":52500,"book_value_yen":33000000,"prior_shares":52500,"prior_book_value_yen":34000000,"purpose_ja":"当社医薬事業における販売取引関係の維持・強化のために保有しています。","reciprocal":"有","pct_outstanding":0.2389818009668521,"pct_unavailable":null,"pct_basis_period_end":"2023-03-31","pct_share_classes":1,"pct_of_holder_equity":0.004077381283337226,"pct_of_holder_assets":0.0035050823694356818,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":809343000000,"holder_total_assets_yen":941490000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"日本ケミファ株式会社","holder_name_en":"NIPPON CHEMIPHAR CO., LTD.","holder_sec_code":"4539","doc_id":"S100YBOB","period_end":"2026-03-31","holder_table":"reporting","shares":36002,"book_value_yen":33000000,"prior_shares":36002,"prior_book_value_yen":31000000,"purpose_ja":"（保有目的）医薬品事業における取引先であり、良好な取引関係の維持・強化を図るため（定量的な保有効果）（注）２","reciprocal":"無","pct_outstanding":0.17513937400881485,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.16914402870322912,"pct_of_holder_assets":0.06602905278322461,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":19510000000,"holder_total_assets_yen":49978000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"わかもと製薬株式会社","holder_name_en":"WAKAMOTO PHARMACEUTICAL CO.,LTD.","holder_sec_code":"4512","doc_id":"S100YDBU","period_end":"2026-03-31","holder_table":"reporting","shares":31804,"book_value_yen":29291000,"prior_shares":31804,"prior_book_value_yen":28210000,"purpose_ja":"同社傘下の企業が医薬事業における顧客であり、取引関係の維持・強化のため保有しています。","reciprocal":"有","pct_outstanding":0.15471731156536714,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.2439172455096901,"pct_of_holder_assets":0.17752544045443022,"holder_equity_basis":"parent_only","holder_equity_yen":12008581000,"holder_total_assets_yen":16499607000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"日本新薬株式会社","holder_name_en":"Nippon Shinyaku Co., Ltd.","holder_sec_code":"4516","doc_id":"S100YGRG","period_end":"2026-03-31","holder_table":"reporting","shares":27504,"book_value_yen":25000000,"prior_shares":27504,"prior_book_value_yen":24000000,"purpose_ja":"医薬品事業の販売取引関係の維持・強化を目的に株式を保有しています。定量的な保有効果を示す事が困難なことから記載は省略していますが、「保有目的の合理性」と保有資産としての「経済的合理性」を検証し、2026年4月の取締役会において検証結果を確認、保有の可否を判断しています。","reciprocal":"無","pct_outstanding":0.13379904846226442,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.008574829103655965,"pct_of_holder_assets":0.0072179443871820854,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":291551000000,"holder_total_assets_yen":346359000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"日本化薬株式会社","holder_name_en":"NIPPON KAYAKU CO.,LTD.","holder_sec_code":"4272","doc_id":"S100YD4R","period_end":"2026-03-31","holder_table":"reporting","shares":19000,"book_value_yen":17000000,"prior_shares":19000,"prior_book_value_yen":16000000,"purpose_ja":"（保有目的）ライフサイエンス事業領域における販売先として関係の維持、強化を図るため（定量的な保有効果）　（注）1","reciprocal":"有","pct_outstanding":0.09242953464161664,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.006069174306686088,"pct_of_holder_assets":0.004263472573331728,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":280104000000,"holder_total_assets_yen":398736000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"鳥居薬品株式会社","holder_name_en":"TORII PHARMACEUTICAL CO., LTD.","holder_sec_code":"4551","doc_id":"S100VH2F","period_end":"2024-12-31","holder_table":"reporting","shares":19368,"book_value_yen":17000000,"prior_shares":19368,"prior_book_value_yen":15000000,"purpose_ja":"医薬品の販売等における円滑な取引関係を維持するために取得後、継続保有（注）２","reciprocal":"有","pct_outstanding":0.09215353212384202,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.013987970345502868,"pct_of_holder_assets":0.012085537166581357,"holder_equity_basis":"parent_only","holder_equity_yen":121533000000,"holder_total_assets_yen":140664000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"参天製薬株式会社","holder_name_en":"SANTEN PHARMACEUTICAL CO., LTD.","holder_sec_code":"4536","doc_id":"S100YDH1","period_end":"2026-03-31","holder_table":"reporting","shares":16261,"book_value_yen":15000000,"prior_shares":16261,"prior_book_value_yen":14000000,"purpose_ja":"当社医薬品等の販売契約があり、眼科領域における事業関係の強化を図ることを目的に保有しています。（注）","reciprocal":"有","pct_outstanding":0.07910508751617516,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.005050692113175909,"pct_of_holder_assets":0.003545822666316812,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":296989000000,"holder_total_assets_yen":423033000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"日医工株式会社","holder_name_en":"Nichi-Iko Pharmaceutical Co., Ltd.","holder_sec_code":"4541","doc_id":"S100OLZH","period_end":"2022-03-31","holder_table":"reporting","shares":23240,"book_value_yen":15000000,"prior_shares":23240,"prior_book_value_yen":17000000,"purpose_ja":"(保有目的)当社の販売先である医薬品卸であり、販売協力関係構築を目的として保有しております。","reciprocal":"有（注２）","pct_outstanding":0.10297766749379653,"pct_unavailable":null,"pct_basis_period_end":"2022-03-31","pct_share_classes":1,"pct_of_holder_equity":0.11199044348215619,"pct_of_holder_assets":0.005756853534132384,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":13394000000,"holder_total_assets_yen":260559000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"ライオン株式会社","holder_name_en":"Lion Corporation","holder_sec_code":"4912","doc_id":"S100XU1E","period_end":"2025-12-31","holder_table":"reporting","shares":5250,"book_value_yen":4000000,"prior_shares":5250,"prior_book_value_yen":4000000,"purpose_ja":"主に一般用消費財事業における製品販売等の取引先であり、同社との取引関係の維持・強化のため保有しております。","reciprocal":"有","pct_outstanding":0.025539739835183546,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.00123944150765665,"pct_of_holder_assets":0.0007567215794292806,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":322726000000,"holder_total_assets_yen":528596000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社カイノス","holder_name_en":"KAINOS Laboratories, Inc.","holder_sec_code":"4556","doc_id":"S100W0MS","period_end":"2025-03-31","holder_table":"reporting","shares":3000,"book_value_yen":2661000,"prior_shares":3000,"prior_book_value_yen":2610000,"purpose_ja":"取引・協力関係の維持強化のため保有しております。（注）","reciprocal":"無","pct_outstanding":0.014274091097249383,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.03927572087404936,"pct_of_holder_assets":0.03028977100432275,"holder_equity_basis":"parent_only","holder_equity_yen":6775178000,"holder_total_assets_yen":8785144000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社メディパルホールディングス","holder_name_en":"MEDIPAL HOLDINGS CORPORATION","holder_sec_code":"7459","doc_id":"S100YI1C","period_end":"2026-03-31","holder_table":"reporting","shares":1886,"book_value_yen":1000000,"prior_shares":1886,"prior_book_value_yen":1000000,"purpose_ja":"・事業の円滑な取引関係維持のため保有しております。 ・定量的な保有効果については、（注）１に記載しております。","reciprocal":"有","pct_outstanding":0.00917484749126784,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.00012572306477629465,"pct_of_holder_assets":5.202908217577297e-05,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"フマキラー株式会社","holder_name_en":"FUMAKILLA LIMITED","holder_sec_code":"4998","doc_id":"S100YGPK","period_end":"2026-03-31","holder_table":"reporting","shares":null,"book_value_yen":null,"prior_shares":6138,"prior_book_value_yen":5000000,"purpose_ja":"販売取引関係の維持・発展のため保有していましたが、保有目的を検討した結果、2025年度において売却しました。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":29327000000,"holder_total_assets_yen":68556000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社ツムラ","holder_name_en":"TSUMURA & CO.","holder_sec_code":"4540","doc_id":"S100YFC1","period_end":"2026-03-31","holder_table":"reporting","shares":null,"book_value_yen":null,"prior_shares":19368,"prior_book_value_yen":17000000,"purpose_ja":"医薬品販売等の取引関係を維持・強化し、中長期的な企業価値の向上のため保有しておりましたが、当事業年度中に全株式を売却しています。","reciprocal":"無(注)２","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":371603000000,"holder_total_assets_yen":592766000000,"implausible":false,"reciprocal_held_both_ways":false}],"reclassified":[],"reclassified_note":"As filed, from the annual report's 保有目的を変更した投資株式 table. direction=to_pure means the filer moved the holding from a policy shareholding to 純投資目的 (pure investment); the shares are not necessarily sold, and the position leaves the named policy table in the year of the change. direction=to_policy is the reverse. fy_of_change_ja is the fiscal year the filer states the change took effect, verbatim — some filers list more than one. A filing repeats these rows for several years after the change, so this is a standing disclosure, not a one-year event.","implausible_note":"A row is flagged implausible when its two filed numbers are mutually impossible — book value ÷ shares of ¥1,000,000 or more, which no listed Japanese share reaches. It is a filer tagging error (a value entered at the wrong scale, or a share count in thousands), not an extraction error: the values match the filing's XBRL exactly. Flagged rows are still returned, exactly as filed, but are excluded from the yen aggregates here and counted in excluded_positions / excluded_yen so the exclusion is visible.","notes":[{"holder_table":"largest","note_no":"1","text_ja":"（注）当社は、特定投資株式における定量的な保有効果の記載が困難であるため、保有の合理性を検証した方法について記載いたします。当社は、期末時点の保有株式について、純投資株式の保有便益とともに、政策保有の意義を検証いたしました。2026年３月31日を基準日とした検証の結果、現状保有する政策株式はいずれも保有方針に沿った目的で保有していることを確認いたしました。"},{"holder_table":"reporting","note_no":"1","text_ja":"（注）当社は、特定投資株式における定量的な保有効果の記載が困難であるため、保有の合理性を検証した方法について記載いたします。当社は、期末時点の保有株式について、純投資株式の保有便益とともに、政策保有の意義を検証いたしました。2026年３月31日を基準日とした検証の結果、現状保有する政策株式はいずれも保有方針に沿った目的で保有していることを確認いたしました。"}],"notes_note":"The filing's own numbered footnotes to the named policy table, verbatim. The XBRL numbers them (注)1, (注)2 … and gives no link back to a row, so a note is tied to a position only where it names that issuer.","flows":[{"holder_table":"largest","share_class":"listed","issues_increased":2,"acquisition_cost_yen":5000000,"issues_decreased":1,"sale_proceeds_yen":212000000,"entity_scope":"largest_holding_company","share_scope":"listed"},{"holder_table":"largest","share_class":"unlisted","issues_increased":null,"acquisition_cost_yen":null,"issues_decreased":2,"sale_proceeds_yen":120000000,"entity_scope":"largest_holding_company","share_scope":"unlisted"},{"holder_table":"reporting","share_class":"listed","issues_increased":null,"acquisition_cost_yen":null,"issues_decreased":1,"sale_proceeds_yen":236000000,"entity_scope":"parent_only","share_scope":"listed"},{"holder_table":"reporting","share_class":"unlisted","issues_increased":null,"acquisition_cost_yen":null,"issues_decreased":null,"sale_proceeds_yen":null,"entity_scope":"parent_only","share_scope":"unlisted"}],"flows_note":"The filer's own tally, as filed, of how many issues increased or decreased during the year and the yen involved — acquisition cost for increases, sale proceeds for decreases. Read against the reclassification table this separates what was actually sold from what merely changed category. Counts are as filed and are not corrected for filer tagging errors.","no_reduction_measure":"This product holds sale proceeds (売却価額), as filed, for one fiscal year. It does NOT hold a book-value-reduction measure. The two are different measures and must never be presented as equivalent.","scale":{"policy_total_yen":13441000000,"listed_yen":13024000000,"unlisted_yen":417000000,"listed_issues":30,"unlisted_issues":22,"equity_yen":64663000000,"equity_basis":"jgaap_consolidated","total_assets_yen":155685000000,"assets_basis":"jgaap_consolidated","pct_of_equity":20.786230147070196,"pct_of_assets":8.633458586247873,"equity_basis_label":"Consolidated net assets (Japanese GAAP)","assets_basis_label":"Consolidated net assets (Japanese GAAP)","equity_calc":"total policy shareholdings ÷ shareholders' equity × 100, both as filed in this annual securities report","assets_calc":"total policy shareholdings ÷ total assets × 100, both as filed in this annual securities report"},"scale_entities":[{"holder_table":"reporting","share_class":"listed","book_value_yen":6429000000,"issue_count":11,"holder_table_label":"The filer itself","entity_scope":"parent_only","share_scope":"listed"},{"holder_table":"largest","share_class":"listed","book_value_yen":6595000000,"issue_count":19,"holder_table_label":"Largest holder in the group","entity_scope":"largest_holding_company","share_scope":"listed"},{"holder_table":"largest","share_class":"unlisted","book_value_yen":417000000,"issue_count":22,"holder_table_label":"Largest holder in the group","entity_scope":"largest_holding_company","share_scope":"unlisted"}],"scale_history":[{"year":"2022","period_end":"2022-03-31","policy_total_yen":10066000000,"equity_yen":55543000000,"equity_basis":"jgaap_consolidated","pct_of_equity":18.122895774445023,"pct_of_assets":7.35372544435759},{"year":"2023","period_end":"2023-03-31","policy_total_yen":9869000000,"equity_yen":57443000000,"equity_basis":"jgaap_consolidated","pct_of_equity":17.180509374510383,"pct_of_assets":7.154715558552093},{"year":"2024","period_end":"2024-03-31","policy_total_yen":10697000000,"equity_yen":60684000000,"equity_basis":"jgaap_consolidated","pct_of_equity":17.627381187792498,"pct_of_assets":7.262050237610319},{"year":"2025","period_end":"2025-03-31","policy_total_yen":10455000000,"equity_yen":61861000000,"equity_basis":"jgaap_consolidated","pct_of_equity":16.900793714941564,"pct_of_assets":7.0904910783921435},{"year":"2026","period_end":"2026-03-31","policy_total_yen":13441000000,"equity_yen":64663000000,"equity_basis":"jgaap_consolidated","pct_of_equity":20.786230147070196,"pct_of_assets":8.633458586247873}],"scale_note":"The policy total is Official (as filed) — the filing's own total carrying amount for the whole policy bucket, listed and unlisted, summed across the entities the filing discloses. It is a floor: holdings at group companies the filing does not name are disclosed nowhere and are not included. The percentages are calculated, not filed, and carry their formula. equity_basis names which figure the denominator is, because filers report under Japanese, IFRS or US accounting standards and an adopter of the latter two stops tagging the Japanese consolidated figure — a parent-only denominator is a different measure and is labelled as one, never silently mixed with a group figure. Percentages are null where equity or total assets is missing or not positive; missing is never shown as zero.","scale_reference":"ISS's Japan proxy voting guidelines recommend a vote against the top executive at a company that allocates 20 percent or more of its net assets to cross-shareholdings, a policy effective from February 2022. ISS counts unilateral holdings, not only mutual ones.","ownership_calc":"shares held ÷ (issuer's issued shares − treasury shares) × 100, both as filed, the denominator taken from the issuer's own annual securities report nearest the holding's fiscal year end","ownership_note":"Derived, not filed. The denominator is the issuer's own reported issued shares less treasury shares, from its annual report nearest this holding's fiscal year end on either side — pct_basis_period_end gives that date, and it can fall after the holding's date where that report is the closer one. For a single-class listed stock this equals the stake's share of market capitalisation. It is null where the issuer files no annual report we hold; where the issuer's share count moves by half or more across the window, because a split or issue makes the share base indeterminate; and where the result would exceed 100%, which is a data fault rather than a stake. It is less exact where the issuer has more than one share class (pct_share_classes > 1), because treasury shares are reported across all classes.","holder_share_calc":"this position's book value ÷ the holder's shareholders' equity (or total assets) × 100, both as filed in the holder's own annual securities report","holder_share_note":"The mirror of pct_outstanding. That sizes a stake against the ISSUER — how much of the issuer this holder owns. pct_of_holder_equity and pct_of_holder_assets size the same position against the HOLDER: how much of its own capital is committed to this one name. Calculated, not filed. Null where the holder's filing gives no usable denominator, never zero. holder_equity_basis says which accounting figure the denominator is, and a parent_only basis is not comparable with a consolidated one. A position CAN legitimately exceed 100% of equity — a holder whose book equity is smaller than one long-held stake is a real and commercially interesting case, not an error — so no ceiling is imposed. Extreme values are worth checking against the filing: where the position's own two filed numbers are mutually impossible the row is marked `implausible`, but that test catches only scale errors visible per share, so it does not catch every bad figure. The book value and share count are returned alongside so the reader can check.","action_calc":"keyword match over the filing's own stated purpose and table footnotes: 株式分割、株式併合、株式交換、株式移転、会社分割、合併、持株会社、商号変更、公開買付、上場廃止","ratio_calc":"current shares ÷ prior shares where that ratio is an exact whole number (or its exact reciprocal) — the signature of a split or a consolidation rather than a trade","history":[{"year":"2022","period_end":"2022-03-31","named_holdings":33,"book_value_yen":9539000000},{"year":"2023","period_end":"2023-03-31","named_holdings":33,"book_value_yen":9374000000},{"year":"2024","period_end":"2024-03-31","named_holdings":33,"book_value_yen":10621000000},{"year":"2025","period_end":"2025-03-31","named_holdings":32,"book_value_yen":9978000000},{"year":"2026","period_end":"2026-03-31","named_holdings":32,"book_value_yen":13009000000}],"history_note":"One point per annual report filed. Each year's book value is as filed; book values are fair-valued at period end, so a change reflects both trading and market moves.","provenance":{"trust":"official","note":"Figures exactly as filed in each company's 有価証券報告書 (annual securities report), EDINET. Raw filings archived with SHA-256; doc_id links to the source filing."}}